CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development.

Autor: Melese ES; Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada., Franks E; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Cederberg RA; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Harbourne BT; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Shi R; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Wadsworth BJ; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Collier JL; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Halvorsen EC; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada., Johnson F; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada., Luu J; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Oh MH; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada., Lam V; Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada., Krystal G; Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada., Hoover SB; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Raffeld M; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Simpson RM; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Unni AM; Weill Cornell Medicine, New York, NY, USA., Lam WL; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada., Lam S; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Abraham N; Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.; Department of Zoology, University of British Columbia, Vancouver, BC, Canada., Bennewith KL; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada., Lockwood WW; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Bc, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Bc, Canada.

Publikováno v: Oncoimmunology [Oncoimmunology] 2021 Dec 30; Vol. 11 (1), pp. 2010905. Date of Electronic Publication: 2021 Dec 30 (Print Publication: 2022).

IL-33 increases ST2 ⁺ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner.

Autor: Halvorsen EC; Integrative Oncology Department, BC Cancer, Vancouver, BC, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada., Franks SE; Integrative Oncology Department, BC Cancer, Vancouver, BC, Canada., Wadsworth BJ; Integrative Oncology Department, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada., Harbourne BT; Integrative Oncology Department, BC Cancer, Vancouver, BC, Canada., Cederberg RA; Integrative Oncology Department, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada., Steer CA; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.; Terry Fox Laboratory, BC Cancer, Vancouver, BC, Canada., Martinez-Gonzalez I; Terry Fox Laboratory, BC Cancer, Vancouver, BC, Canada., Calder J; Integrative Oncology Department, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada., Lockwood WW; Integrative Oncology Department, BC Cancer, Vancouver, BC, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada., Bennewith KL; Integrative Oncology Department, BC Cancer, Vancouver, BC, Canada.; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Publikováno v: Oncoimmunology [Oncoimmunology] 2018 Oct 16; Vol. 8 (2), pp. e1527497. Date of Electronic Publication: 2018 Oct 16 (Print Publication: 2019).